

Price Waterhouse & Co Chartered Accountants LLP

To
The Board of Directors
Sanofi India Limited
Sanofi House,
CTS No. 117-B, L&T Business Park,
Saki Vihar Road, Powai,
Mumbai – 400 072

1. We have reviewed the unaudited financial results of Sanofi India Limited (the “Company”) for the quart

*Price Waterhouse & Co Chartered Accountants LLP, Nesco IT Building III, 8th Floor, Nesco IT Park
Nesco Complex, Gate No. 3 Western Express Highway, Goregaon East, Mumbai — 400 063*

T: +91(22) 61198000, F: +91 (22) 61198799

Registered office and Head office: Plot No. Y-14, Block EP, Sector V, Salt Lake Electronic Complex, Bidhan Nagar, Kolkata 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E-300009 (ICAI registration number before conversion was 304026E)

SANOFI INDIA LIMITED

Registered Office : Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.

Corporate Identity Number: L24239MH1956PLC009794

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846

Website: www.sanofiindia.com Email: igrc.sil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2021

Particulars	₹ in Million			
	Quarter ended 31.03.2021 (Unaudited)	Quarter ended 31.12.2020 (Audited)	Quarter ended 31.03.2020 (Unaudited)	Year ended 31.12.2020 (Audited)
1. Revenue from Operations	7,251	7,203	7,845	29,019
2. Other Income	263	162	295	898
3. Total Income (1+2)	7,514	7,365	8,140	29,917
4. Expenses				
(a) Cost of Materials Consumed	1,567	1,483	2,422	5,914
(b) Purchases of stock in trade	1,641	1,609	1,187	6,047
(c) Changes in inventories of finished goods, stock in trade and work in progress	35	68	(207)	575
(d) Employee benefits expense	1,063	1,072	1,203	4,608
(e) Finance costs	4	4	5	18
(f) Depreciation and amortisation expense	204	204	207	822
(g) Other expenses	1,051	1,301	1,473	4,744
Total Expenses	5,565	5,741	6,290	22,728
5. Profit before exceptional item and tax (3-4)	1,949	1,624	1,850	7,189
6. Exceptional item (Refer note 3)	-	78	(504)	(417)
7. Profit before tax (5-6)	1,949	1,702	1,346	6,772
8. Tax expense				
Current Tax	540	467	535	2,110
Deferred Tax	(50)	5	(43)	(114)
9. Profit for the period (7-8)	1,459	1,230	854	4,776
10. Other comprehensive income (OCI) (Net of Tax)	-	(51)	(37)	(88)
11. Total comprehensive income for the period (9+10)	1,459	1,179	817	4,688
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230
13. Other equity	-	-	-	20,960
14. Basic and diluted earnings per share (not annualised)	63.35	53.41	37.08	207.38

RAJARAM
NARAYANAN

Digitally signed by
RAJARAM NARAYANAN
Date: 2021.04.27
12:30:00 +05'30'

ASHA
RAMANATHAN

Digitally signed by ASHA
RAMANATHAN
Date: 2021.04.27
13:45:47 +05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated April 27, 2021

Notes:

1. The above Results have been reviewed by the Audit Committee at its meeting held on April 26, 2021 and approved by the Board of Directors of the Company at its Meeting held on April 27, 2021. The statutory auditors have carried out a limited review of the above results for the quarter ended March 31, 2021.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
3. During the year ended December 31, 2020, the Company had transferred its Ankleshwar manufacturing facility to Zentiva Private Limited. Upon completion of the transaction, the final consideration after working capital adjustments came to ₹ 3,001 million, out of which ₹ 2,728 million had been received during the previous year. The balance ₹ 273 million has been received during the quarter ended March 31, 2021.

The Company during the year December 31, 2020 had accounted for an impairment charge and other incidental expenses on account of the maintenance capital that was immediately impaired and information technology, legal & professional services costs and government taxes, aggregating ₹ 417 million, which had been disclosed as an exceptional item.

4. Sales performance for the quarter ended March 31, 2021 is not comparable with quarter ended March 31, 2020 due to lower export sales on account of transfer of Ankleshwar manufacturing facility during the previous year.
5. The Sales performance for the quarter ended March 31, 2021 and year ended December 31, 2020 has been impacted due to COVID-19 pandemic. The impact assessment of COVID-19 pandemic is a continuing process given the uncertainties associated with its nature and duration.
6. The figures for the quarter ended December 31, 2020 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2020 and the unaudited published year-to-date figures up to September 30, 2020, which was subject to limited review, being the date of the end of the third quarter of the said financial year.
7. The Company has a single business segment namely 'Pharmaceutical Business'.
8. The figures for the previous period/year have been regrouped/reclassified, wherever necessary to conform to current period/year classification.

ASHA**RAMANATHAN**

Digitally signed by ASHA
RAMANATHAN
Date: 2021.04.27 13:47:21
+05'30'

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the review report dated April 27, 2021

April 27, 2021

SANOFI INDIA LIMITED**RAJARAM
NARAYANAN**

Digitally signed by
RAJARAM NARAYANAN
Date: 2021.04.27
12:31:00 +05'30'

**RAJARAM NARAYANAN
MANAGING DIRECTOR
DIN: 02977405**